Bennedjai Amin, Theillac Vincent, Akesbi Jad, Adam Raphaël, Rodallec Thibaut, Keilani Chafik, Blumen-Ohana Esther, Labbé Antoine, Nordmann Jean-Philippe
Department of Ophthalmology 2, Quinze-Vingts National Ophthalmology Hospital, IHU FOReSIGHT, University Paris Descartes, Paris, France.
Department of Ophthalmology 3, Quinze-Vingts National Ophthalmology Hospital, IHU FOReSIGHT, Paris Saclay University, Paris, France.
J Ophthalmol. 2020 Oct 13;2020:3439182. doi: 10.1155/2020/3439182. eCollection 2020.
To assess the safety and efficacy of selective laser trabeculoplasty (SLT) for ocular hypertension (OHT) induced by a dexamethasone (DEX) intravitreal implant.
We performed a retrospective study of patients who underwent an SLT procedure for ocular hypertension induced by injection of a DEX intravitreal implant. Patients had, at least, one injection of the DEX-implant for symptomatic macular edema. SLT was delivered to 360° of the trabecular meshwork in two sessions. The primary outcome was a decrease in IOP, evaluated at one, three, and six months after the SLT procedure.
Twenty-six eyes of 22 patients were included. The mean intraocular pressure (IOP) measured after DEX-implant injection was 25.4 ± 5.4 mmHg, and the mean increase in IOP was 35.8 ± 14.6%. The mean follow-up after SLT was 18.3 ± 7.7 months. After SLT, the mean IOP dropped by 30.9% at one month (16.9 ± 4.5 mmHg, =0.01), 33.6% at three months (16.0 ± 2.7 mmHg, < 0.01), and 34.9% at six months (15.6 ± 2.1 mmHg, < 0.01). Each patient had a minimum follow-up of 6 months after SLT. Eight eyes (31%) received a second DEX-implant injection after the SLT procedure without experiencing an increase in the IOP above 21 mmHg or >20%. No glaucoma surgery was required during the follow-up. The mean number of medications (1.65 ± 1.36) was significantly reduced at one (1.19 ± 1.20, =0.04), three (0.96 ± 1.03, < 0.01), and six months (0.77 ± 0.95, < 0.01) after SLT.
SLT is an effective and safe procedure to control OHT following DEX-implant intravitreal injection.
评估选择性激光小梁成形术（SLT）治疗地塞米松（DEX）玻璃体内植入物所致高眼压症（OHT）的安全性和有效性。
我们对因DEX玻璃体内植入物注射导致高眼压而接受SLT手术的患者进行了一项回顾性研究。患者因症状性黄斑水肿至少接受过一次DEX植入物注射。SLT分两次对小梁网360°进行治疗。主要结局是在SLT手术后1个月、3个月和6个月评估眼压降低情况。
纳入22例患者的26只眼。DEX植入物注射后测得的平均眼压（IOP）为25.4±5.4mmHg，眼压平均升高35.8±14.6%。SLT后的平均随访时间为18.3±7.7个月。SLT后，1个月时平均眼压下降30.9%（16.9±4.5mmHg，P=0.01），3个月时下降33.6%（16.0±2.7mmHg，P<0.01），6个月时下降34.9%（15.
